TrovaGene (NASDAQ:TROV) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

7.2% of TrovaGene shares are owned by institutional investors. Comparatively, 83.4% of Vericel shares are owned by institutional investors. 2.0% of TrovaGene shares are owned by company insiders. Comparatively, 4.7% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares TrovaGene and Vericel’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TrovaGene $380,000.00 38.84 -$16.46 million ($8.26) -0.44
Vericel $90.86 million 8.60 -$8.14 million ($0.14) -127.43

Vericel has higher revenue and earnings than TrovaGene. Vericel is trading at a lower price-to-earnings ratio than TrovaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for TrovaGene and Vericel, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TrovaGene 0 0 3 0 3.00
Vericel 0 1 4 0 2.80

TrovaGene currently has a consensus target price of $23.33, suggesting a potential upside of 535.79%. Vericel has a consensus target price of $18.98, suggesting a potential upside of 6.39%. Given TrovaGene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe TrovaGene is more favorable than Vericel.


This table compares TrovaGene and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TrovaGene -4,354.76% -142.49% -102.44%
Vericel -8.96% -7.58% -5.59%

Volatility and Risk

TrovaGene has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Vericel has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500.


Vericel beats TrovaGene on 10 of the 14 factors compared between the two stocks.

TrovaGene Company Profile

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.